{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065087","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.424925+00:00","generated_at":"2026-06-07T23:14:50.943198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study","bullets":["Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).","Net loss $28.1M ($1.33/diluted share) vs $26.3M ($1.27) in Q4 2022; FY loss $133.8M ($6.38) vs $121.8M ($5.91).","Cash and marketable securities $370M; expects to fund operations through fiscal 2027.","FY2024 guidance: R&D $100-120M (down from $163.5M actual), G&A $45-50M (down from $52M).","Initiated Phase 2a challenge study for RSV candidate EDP-323; data expected Q3 2024. Advancing EDP-938 Phase 2 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065087","json":"https://secwatch.observer/filing/0000950170-23-065087.json","markdown":"https://secwatch.observer/filing/0000950170-23-065087.md","text":"https://secwatch.observer/filing/0000950170-23-065087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/0000950170-23-065087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/enta-20231120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:14:50.943198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"508ff97d41ac951309fecc59c86b2a8550a2ff07","claim":"ENANTA PHARMACEUTICALS INC updated its fiscal fourth quarter and year ended September 30, 2023 guidance (lowered).","evidence_excerpt":"On November 20, 2023, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/0000950170-23-065087-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter and year ended September 30, 2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}